Europe
The landmark Human Challenge Programme deliberately exposed 36 young and healthy participants ages 18 to 30 with no immunity to the SARS-CoV-2 virus for 14 days.
Sanofi inked a pact with IGM Biosciences that could pass $6 billion. However, Sanofi CEO Paul Hudson’s pay had a drop of about 3.7%, according to the company’s annual filing.
Several employees at three biopharma firms are not having a very good week, as Zealand Pharma, Merck and Orchard Therapeutics all announced job cuts.
After manufacturing more than 2.6 billion doses of the Comirnaty COVID-19 vaccine together, Pfizer’s partner BioNTech is reporting skyrocketing profits.
Four companies, Pipeline Therapeutics, Prothena, Neuroplast, and Taysha Gene Therapies, announced launches of clinical trials in the CNS space.
Sanofi and IGM Biosciences inked a collaboration deal for oncology, immunology and inflammation that could surpass $6 billion.
AstraZeneca will showcase its early oncology portfolio at the American Association for Cancer Research set to begin on April 8.
The study suggests that artificial sweeteners, which are readily available in coffee shops and used in diet soft drinks, increase the risks of breast cancer and obesity.
The Phase II trial is evaluating zepzelca as a monotherapy in patients with urothelial carcinoma, large cell neuroendocrine carcinoma of the lung and HRD tumors.
Terms of the deal provide BiondVax with an option for a worldwide license to develop and commercialize the NanoAbs, which are also known as VHH-antibodies or nanobodies.
PRESS RELEASES